Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on March 11, 2026 reporting Item 8.01 (Other Events). Priced $550M convertible senior notes due 2031, upsized from initial $350M offering: 57% increase signals strong institutional demand.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Priced $550M convertible senior notes due 2031, upsized from initial $350M offering: 57% increase signals strong institutional demand
- Private placement via Rule 144A, sold only to qualified institutional buyers: no SEC registration, limits retail participation
- Convertible structure means potential dilution to common shareholders upon conversion
- Proceeds use and conversion premium/interest rate not disclosed in this filing: key terms pending in full prospectus
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.